MK0777

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Anxiety DisorderAnxiety DisordersGeneralized Anxiety Disorder

Phase 2

Treatment of Patients With Anxiety Disorder (0777-022)

CompletedNCT00539578

Merck Sharp & Dohme LLCGeneralized Anxiety Disorder

Start: 2002-09-30End: 2003-02-28Updated: 2015-11-02

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)

CompletedNCT00543920

Merck Sharp & Dohme LLCAnxiety Disorders

Start: 2002-08-31End: 2003-02-28Updated: 2015-11-26

GEM 1.5 mg b.i.d. to 4.5 mg b.i.d. Versus Lorazepam in GAD (0777-026)

CompletedNCT00546624

Merck Sharp & Dohme LLCAnxiety Disorder

Start: 2002-11-30End: 2003-02-28Updated: 2015-11-02

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

CompletedNCT00703833

Merck Sharp & Dohme LLCGeneralized Anxiety Disorder

Start: 2002-09-30End: 2003-02-28Updated: 2015-11-02